-
Investigational new drug (IND) application of SC-102 was approved by CDE of NMPA
On August 8, 2024, Conjustar Biologics announced that the investigational new drug (IND) application for the company's second peptide-drug conjugate (PDC), SC-102 for Injection, for the treatment of advanced malignant solid tumors expressing EphA2, was approved by the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration.
2024-09-02
-
SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug
On May 31, 2024, Conjustar Biologics announced that its Nectin-4 targeting PDC drug SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug.
2024-05-31
-
First in China: SC-101, a Peptide Drug Conjugate (PDC), has been approved by the Chinese National Medical Products Administration.
First in China: the Phase Ⅰ FIH study of SC-101, a Nectin-4-targeting Peptide Drug Conjugate (PDC), has been approved by the Chinese National Medical Products Administration.
2024-01-03
